Abstracts tagged "interleukins (IL)"

Abstract Number: 2145 • 2015 ACR/ARHP Annual Meeting
Ixekizumab Improves Physical Function, Quality of Life, and Work Productivity in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients with Active Psoriatic Arthritis
Alice B. Gottlieb¹, Philip J. Mease², Raquel S. Cuchacovich^3,4, Catherine L. Shuler⁵, Chen-Yen Lin⁵, Russel T. Burge⁵, Suvajit Samanta⁵, Chin H. Lee⁵ and Dafna D. Gladman⁶, ¹Dermatology, Tufts Medical Center, Boston, MA, ²Department of Rheumatology, Swedish Medical Center and University of Washington, Seattle, WA, ³School of Medicine, Rheumatology Division, Indiana University, Indianapolis, IN, ⁴Bio Medicines Business Unit/Autoimmune Medical, Eli Lilly and Company, Indianapolis, IN, ⁵Eli Lilly and Company, Indianapolis, IN, ⁶Department of Medicine, Division of Rheumatology, University of Toronto, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA) is a chronic immune-mediated inflammatory disease associated with psoriasis, peripheral arthritis, enthesitis, dactylitis, and spondylitis. PsA has a significant negative impact…
Abstract Number: 2460 • 2015 ACR/ARHP Annual Meeting
B10 Cells May be Involved in Controlling Disease Activity in Polyarticular Juvenile Idiopathic Arthritis Patients
Qianzi Zhao¹ and Lawrence K. Jung², ¹Rheumatology, Children's National Medical Center, Washington, DC, ²Pediatric Rheumatology, Children's National Medical Center, Washington, DC
Background/Purpose: In addition to antibodies production, B cells have been shown to have down-regulatory function on immune response in both mouse and human. The down-regulatory…
Abstract Number: 2848 • 2015 ACR/ARHP Annual Meeting
Network Meta-Analysis of Tumor Necrosis Factor, Interleukins, and Phosphodiesterase-4 Inhibitor in the Treatment of Psoriatic Arthritis
Vibeke Strand¹, M. Elaine Husni², William Reichmann³, Keith Betts⁴, Jenny Griffith⁵, Yan Song³, Marci Beppu⁶ and Arijit Ganguli⁵, ¹Biopharmaceutical Consultant, Portola Valley, CA, ²Rheumatology Dept A50, Cleveland Clinic Foundation, Cleveland, OH, ³Analysis Group Inc., Boston, MA, ⁴Analysis Group, Inc., Boston, MA, ⁵AbbVie Inc., North Chicago, IL, ⁶Abbvie, Newcastle, WA
Background/Purpose: Multiple disease-modifying therapies for treatment of psoriatic arthritis (PsA) are available. However, there are limited data directly comparing these biologic therapies and the recently…
Abstract Number: 2853 • 2015 ACR/ARHP Annual Meeting
Secukinumab Improves Skin Symptoms and Physical Functioning Compared with Ustekinumab in Patients with Moderate to Severe Psoriasis with Concomitant Psoriatic Arthritis: Subanalysis of a Randomized, Double Blind, Parallel-Group, Active Comparator-Controlled Phase 3b Trial
Alice B. Gottlieb¹, Diamant Thaci², Andrew Blauvelt³, Marina Milutinovic⁴ and Shephard Mpofu⁴, ¹Tufts Medical Center and Tufts University School of Medicine, Boston, MA, ²Comprehensive Center for Inflammation Medicine, University Hospital Schleswig-Holstein, Lübeck, Germany, ³Research Excellence & Personalized Patient Care, Oregon Medical Research Center, Portland, OR, ⁴Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Psoriatic arthritis (PsA) is a common comorbidity in patients (pts) with psoriasis. In the ongoing Phase 3b CLEAR study (NCT02074982), secukinumab, a fully human…
Abstract Number: 2883 • 2015 ACR/ARHP Annual Meeting
Relationship Between Improvements in Fatigue and Signs & Symptoms of Active Psoriatic: Arthritis a Sub-Analysis of a Phase 3 Study with Secukinumab
Laure Gossec¹, Tore K. Kvien², Philip G. Conaghan³, Mikkel Østergaard⁴, Juan D. Cañete⁵, C. Gaillez⁶, Shephard Mpofu⁶, Bintu Sherif⁷ and Steffen Jugl⁸, ¹Rheumatology Department, Paris 06 University,Hôpital Pitié Salpêtrière, Paris, France, ²Dept of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³University of Leeds & NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, ⁴Center for Rheumatology and Spine Diseases, Glostrup Hospital, Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Rigshospitalet - Glostrup, University of Copenhagen, Denmark, Glostrup, Denmark, ⁵Rheumatology, Hospital Clinic and IDIBAPS, Barcelona, Spain, ⁶Novartis Pharma AG, Basel, Switzerland, ⁷RTI Health Solutions, Durham, NC, ⁸BF I&D GPA, Health Economics and Outcomes Research, Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Fatigue is highly important to patients (pts) with psoriatic arthritis (PsA). Secukinumab, an anti-interleukin-17A monoclonal antibody, significantly improved the signs and symptoms of active…
Abstract Number: 2039 • 2014 ACR/ARHP Annual Meeting
Among Persons Assayed with Lower Serum Interleukin-1 Beta (IL-1β) Levels, Serum Androstenedione (Δ4A) and Testosterone (T) Were Significantly Lower in a Community-Based Cohort of Rheumatoid Arthritis Multi-Years before Clinical Onset (Pre-RA) Than in Non-RA Matched Control (CN) Subjects
Alfonse T. Masi, Azeem A. Rehman and Jean C. Aldag, Medicine, University of Illinois College of Medicine at Peoria, Peoria, IL
Background/Purpose: Dysregulations in androgenic-anabolic (A-A) steroids and cytokines are recognized in RA and pre-RA subjects (Rheum Dis Clin N Am 2005; 31: 131-60). However, deviations…
Abstract Number: 81 • 2014 ACR/ARHP Annual Meeting
Elevated Peripheral Blood Leukocyte Inflammatory Gene Expression in Radiographic Progressors with Symptomatic Knee Osteoarthritis: NYU and OAI Cohorts
Mukundan Attur¹, Alexander Statnikov², Svetlana Krasnokutsky Samuels¹, Virginia B. Kraus³, Joanne Jordan⁴, Braxton D. Mitchell⁵, Michelle Yau⁶, Jyoti Patel¹, Constantin F. Aliferis², Marc C. Hochberg⁷, Jonathan Samuels¹ and Steven B. Abramson⁸, ¹Rheumatology, NYU Langone Medical Center, New York, NY, ²Center for Health Informatics and Bioinformatics, NYU Langone Medical Center, New York, NY, ³Medicine/Rheumatology, Duke University Medical Center, Durham, NC, ⁴Thurston Arthritis Research Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁵Departments of Medicine and Epidemiology & Public Health, University of Maryland School of Medicine, Baltimore, MD, ⁶Epidemiology and Public Health, University of Maryland, Baltimore,, MD, ⁷Medicine, University of Maryland School of Medicine, Baltimore, MD, ⁸Dept of Rheumatology/Medicine, NYU Langone Medical Center, New York, NY
Background/Purpose: We and others have demonstrated low grade inflammation exists in OA joint tissues, where it may contribute to disease pathogenesis. In the current studies…
Abstract Number: 1816 • 2014 ACR/ARHP Annual Meeting
Toll-like Receptor 4-Induced Interleukin-1 Defines the Intestinal Microbiome and Mucosal Immune Response in Arthritis-Prone IL-1 Receptor Antagonist Deficient Mice
Tom Ederveen¹, Rebecca Rogier², Jos Boekhorst¹, Harm Wopereis³, Johan Garssen³, Sacha van Hijum¹, Fons A.J. van de Loo², Marije I. Koenders², Wim B. van den Berg² and Shahla Abdollahi-Roodsaz⁴, ¹Centre for Molecular Bioinformatics Nijmegen (CMBI), Radboud university medical center, Nijmegen, Netherlands, ²Experimental Rheumatology, Radboud university medical center, Nijmegen, Netherlands, ³Danone Research, Wageningen, Netherlands, ⁴Rheumatology, Radboud university medical center, Nijmegen, Netherlands
Background/Purpose Interleukin-1 (IL-1) plays a pivotal role in inflammation and autoimmunity. Mice deficient in the IL-1 receptor antagonist (IL-1Ra-/-) spontaneously develop a T cell-driven autoimmune…
Abstract Number: 1746 • 2014 ACR/ARHP Annual Meeting
Involvement of IL-17-Producing MAIT Cells in the Pathogenesis of Rheumatoid Arthritis
Eri Hayashi¹, Asako Chiba², Mie Kitagaichi³, Kurisu Tada³, Ken Yamaji⁴, Naoto Tamura¹, Yoshinari Takasaki³ and Sachiko Miyake², ¹Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, ²Immunology, Juntendo University School of Medicine, Tokyo, Japan, ³Department of Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, ⁴Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan
Background/Purpose: Mucosal-associated invariant T (MAIT) cells are a subset of innate-like lymphocytes which are restricted by the MHC-related molecule-1 (MR1) and express a semi-invariant TCRα…
Abstract Number: 1732 • 2014 ACR/ARHP Annual Meeting
Attenuation of Sclerodermatous Graft Versus Host Disease (sclGVHD) in IL4RA Receptor-Deficient Mice
Katia Urso¹, Kelly Tsang², Robert Lafyatis³ and Antonios O. Aliprantis², ¹Rheumatology, Brigham and Women's Hospital, Boston, MA, ²Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ³Rheumatology, Boston University School of Medicine, Boston, MA
Background/Purpose Scleroderma is a rare autoimmune disease characterized by the accumulation of fibrotic tissue in multiple organs including the skin, gut and lungs. To date,…
Abstract Number: 1511 • 2014 ACR/ARHP Annual Meeting
COVA322: A Clinical Stage Bispecific TNF/IL-17A Inhibitor for the Treatment of Inflammatory Diseases
Wibke Lembke, Bernd Schlereth, Julian Bertschinger, Dragan Grabulovski and Mathias Locher, Covagen AG, Schlieren, Switzerland
Background/Purpose: Biologic therapeutics such as TNF inhibitors have revolutionized the treatment of inflammatory diseases, including rheumatoid arthritis (RA), psoriasis and psoriatic arthritis. However, there is still…
Abstract Number: 1491 • 2014 ACR/ARHP Annual Meeting
Discovery and Characterization of COVA322, a Clinical Stage Bispecific TNF/IL-17A Inhibitor for the Treatment of Inflammatory Diseases
Dragan Grabulovski, Michela Silacci, Wibke Lembke, Wenjuan Zha, Richard Woods, Roger Santimaria, Julian Bertschinger and Mathias Locher, Covagen AG, Schlieren, Switzerland
Background/Purpose: Biologics such as TNF inhibitors have revolutionized the treatment of inflammatory diseases including rheumatoid arthritis (RA), psoriasis and psoriatic arthritis. However, recent data suggest that…
Abstract Number: 1492 • 2014 ACR/ARHP Annual Meeting
Safety and Tolerability of NNC01140006, an Anti-IL-21 Monoclonal Antibody, at Multiple s.c. Dose Levels in Patients with Rheumatoid Arthritis
Frank Wagner¹, Birte Skrumsager² and Sergey Fitilev³, ¹Charité Research Org GmbH, Berlin, Germany, ²Novo Nordisk A/S, Søborg, Denmark, ³Department of Clinical Pharmacology, Municipal Clinic #2, Moscow, Russia
Background/Purpose A phase 1, randomised, double-blind, placebo-controlled, dose-escalation trial was conducted to assess the safety and tolerability of the anti-IL-21-antibody NNC0114-0006, in patients with active…
Abstract Number: 1459 • 2014 ACR/ARHP Annual Meeting
IL-22 Secreted By NKp44+NK Cells Promote the Proliferation of Synovium in Patients with Rheumatoid Arthritis By Activation of STAT3
Junqing Zhu¹, Juan Li¹ and Xiaoguang Chen², ¹Nanfang Hospital, College of Traditional Chinese Medicine, Southern Medical University, Guangzhou, China, ²School of Public Health and Tropical Medicine, Southern Medical University, Guangzhou, China
Background/Purpose: Although CD3-CD56+NKp44+ natural Killer cells (NKp44+NK cells) have been linked to autoimmune diseases including inflammatory bowel disease, ankylosing spondylitis, and primary Sjogren's syndrome, the…
Abstract Number: 1253 • 2014 ACR/ARHP Annual Meeting
Anakinra – a Promising New Therapy for Idiopathic Recurrent Pericarditis
Sonia Jain¹, Charat Thongprayoon², Raul Espinosa¹, Sharonne Hayes¹, Kyle Klarich¹, Kevin Moder³, Nandan Anavekar¹, Jae Oh¹ and Eric L. Matteson⁴, ¹Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, ²Department of Medicine, Mayo clinic, Rochester, MN, ³Division of Rheumatology, Mayo Clinic, Rochester, MN, ⁴Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose Idiopathic recurrent pericarditis (IRP) is a debilitating condition that can be recalcitrant to conventional therapy. Some patients develop steroid dependency with the attendant risks…

« Previous Page
1
…
5
6
7
8
9
…
12
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].